Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient

Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachpekidis, Christos, Dimitrakopoulou-Strauss, Antonia, Delorme, Stefan, Goldschmidt, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745397/
https://www.ncbi.nlm.nih.gov/pubmed/29244720
http://dx.doi.org/10.3390/diagnostics7040061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745397/
https://www.ncbi.nlm.nih.gov/pubmed/29244720
http://dx.doi.org/10.3390/diagnostics7040061

Ejemplares similares